欧洲S3指南:黏膜类天疱疮的诊断与管理(第一部分)
欧洲皮肤病与性病学会(EADV)自身免疫性大疱性疾病工作组联合相关学科及患者组织制定S3共识指南,系统检索MEDLINE和EMBASE截至2019年6月的文献。第一部分涵盖方法学、MMP临床定义、流行病学、亚型、免疫病理特征、疾病评估与结局评分。
要点
- MMP以黏膜受累为主,可呈单部位或多部位受累。
- 自身抗体主要针对BP180、BP230、层粘连蛋白332和VII型胶原。
- 可用MMPDAI、ABSIS、ODSS等评分及DLQI等PROM评估。
核心结论
- 本S3共识指南第一部分明确了MMP的临床定义、亚型、免疫病理特征及疾病评估工具。
研究设计与样本
- 由EADV自身免疫性大疱性疾病工作组联合相关学科医师及患者组织制定的S3共识指南,系统检索MEDLINE和EMBASE截至2019年6月的文献。
主要发现
- MMP是一组以黏膜受累为主的自身免疫性皮肤黏膜水疱病,呈慢性病程,可累及口腔、眼、鼻、鼻咽、肛门生殖器、喉及食管黏膜。
- MMP患者可表现为单部位或多部位受累。
- 患者自身抗体主要针对BP180(BPAG2,XVII型胶原)、BP230、层粘连蛋白332和VII型胶原。
关键数值与推荐
- 可用的疾病评估评分包括黏膜类天疱疮疾病面积指数(MMPDAI)、自身免疫性大疱性皮肤病强度评分(ABSIS)、瘢痕性结膜炎评估工具及口腔疾病严重程度评分(ODSS)。
- 患者报告结局测量(PROMs)包括DLQI、ABQOL和TABQOL,可用于评估生活质量以评价治疗干预效果和监测病程。
临床怎么用
- 临床可采用MMPDAI、ABSIS、ODSS等标准化评分评估MMP疾病活动与严重程度。
- 可使用DLQI、ABQOL、TABQOL等PROM评估生活质量并监测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline encompassing a systematic review of the literature until June 2019 in the MEDLINE and EMBASE databases. This first part covers methodology, the clinical definition of MMP, epidemiology, MMP subtypes, immunopathological characteristics, disease assessment and outcome scores. MMP describes a group of autoimmune skin and mucous membrane blistering diseases, characterized by a chronic course and by predominant involvement of the mucous membranes, such as the oral, ocular, nasal, nasopharyngeal, anogenital, laryngeal and oesophageal mucosa. MMP patients may present with mono- or multisite involvement. Patients' autoantibodies have been shown to be predominantly directed against BP180 (also called BPAG2, type XVII collagen), BP230, laminin 332 and type VII collagen, components of junctional adhesion complexes promoting epithelial stromal attachment in stratified epithelia. Various disease assessment scores are available, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI), the Autoimmune Bullous Skin disorder Intensity Score (ABSIS), the 'Cicatrising Conjunctivitis Assessment Tool' and the Oral Disease Severity Score (ODSS). Patient-reported outcome measurements (PROMs), including DLQI, ABQOL and TABQOL, can be used for assessment of quality of life to evaluate the effectiveness of therapeutic interventions and monitor disease course.
引用
- Rashid H, Lamberts A, Borradori L, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol. 2021. PMID: 34245180. doi:10.1111/jdv.17397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。